The stock of X4 Pharmaceuticals Inc. (NASDAQ:XFOR) last traded at $0.99, down -3.88% from the previous session.
Data from the available sources indicates that X4 Pharmaceuticals Inc. (NASDAQ:XFOR) is covered by 6 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $4.50, we find $5.00. Given the previous closing price of $1.03, this indicates a potential upside of 385.44 percent. XFOR stock price is now -45.34% away from the 50-day moving average and -31.62% away from the 200-day moving average. The market capitalization of the company currently stands at $71.53M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
In total, 0 analysts have assigned it a hold rating, and 6 have given it a buy rating. Brokers who have rated the stock have averaged $5.50 as their price target over the next twelve months.
With the price target of $20, Oppenheimer recently initiated with Outperform rating for X4 Pharmaceuticals Inc. (NASDAQ: XFOR). On December 18, 2019, ROTH Capital recently initiated its ‘Buy’ rating on the stock quoting a target price of $20, while ‘Citigroup’ rates the stock as ‘Buy’.
In other news, Ragan Paula, President and CEO sold 6,292 shares of the company’s stock on Jun 03. The stock was sold for $7,613 at an average price of $1.21. Upon completion of the transaction, the President and CEO now directly owns 661,806 shares in the company, valued at $0.66 million. A total of 1.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in XFOR stock. A new stake in X4 Pharmaceuticals Inc. shares was purchased by NEA MANAGEMENT COMPANY, LLC during the first quarter worth $6,458,000. PARKMAN HEALTHCARE PARTNERS LLC invested $941,000 in shares of XFOR during the first quarter. In the first quarter, SUSQUEHANNA INTERNATIONAL GROUP, LLP acquired a new stake in X4 Pharmaceuticals Inc. valued at approximately $149,000. PEAK6 INVESTMENTS LLC acquired a new stake in XFOR for approximately $60,000. GOLDMAN SACHS GROUP INC purchased a new stake in XFOR valued at around $55,000 in the second quarter. In total, there are 67 active investors with 60.80% ownership of the company’s stock.
With an opening price of $1.0400 on Thursday morning, X4 Pharmaceuticals Inc. (NASDAQ: XFOR) set off the trading day. During the past 12 months, X4 Pharmaceuticals Inc. has had a low of $0.86 and a high of $4.20. As of last week, the company has a debt-to-equity ratio of 0.54, a current ratio of 3.00, and a quick ratio of 3.00. The fifty day moving average price for XFOR is $1.8111 and a two-hundred day moving average price translates $1.4478 for the stock.
The latest earnings results from X4 Pharmaceuticals Inc. (NASDAQ: XFOR) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.6, beating analysts’ expectations of -$0.64 by 0.04. This compares to -$0.76 EPS in the same period last year. The company reported revenue of $20.15 million for the quarter, compared to $19.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.41 percent.
X4 Pharmaceuticals Inc.(XFOR) Company Profile
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
